Revelation Biosciences Stock Sinks 12% After Reverse Split Reveal; Retail Traders Eye ‘Bigger News’

Shares of Revelation Biosciences fell 12.4% in after-hours trading Tuesday after the company said that it would be conducting a 1-for-3 reverse stock split. 

The split is expected to be effective before the market opens on July 7. 

Revelation plans to conduct the reverse split to meet Nasdaq's minimum bid requirement.

The reverse split, approved at a special shareholder meeting held on June 23, will affect all outstanding shares and adjust related equity instruments, including options, warrants, and restricted stock units (RSUs). 

Revelation will retain its current ticker symbol “REVB.”

Separately, Revelation stated that enrollment is expected to conclude this month in its Phase 1b trial evaluating Gemini in patients with chronic kidney disease. 

Topline results are expected soon after.

Earlier this year, the company said that Gemini reduced inflammation in lab tests involving human immune cells. 

Cells primed with Gemini showed lower levels of proinflammatory cytokines and higher levels of protective anti-inflammatory markers when exposed to known inflammation triggers, including HMGB-1 and bacterial LPS. 

The company said that similar effects could be observed in patients, supporting Gemini’s potential in treating inflammation-driven conditions.

On Stocktwits, retail sentiment was ‘neutral’ amid ‘low’ message volume.

One user described the 1-for-3 reverse split as “small” and suggested that good news could follow shortly. 

Another user acknowledged the initial panic-driven selloff but argued the situation was different from typical reverse split moves, adding that “bigger news” may be on the way.

Revelation’s stock has declined 92.2% so far in 2025.

For updates and corrections, email newsroom[at]stocktwits[dot]com.